Immunohematology is the branch of medicine that studies how the immune system interacts with blood cells, and its findings underpin virtually every blood transfusion, pregnancy screen, and hemolytic anemia workup performed today. Most people know about the ABO and Rh systems from casual conversation, but the field tracks more than 40 recognized blood group systems, each defined by antigens on the surface of red blood cells that can provoke immune responses. The practical stakes are high: a mismatch between donor and recipient blood can trigger reactions ranging from mild fevers to fatal organ failure, and some of the most dangerous antibodies are among the hardest to detect.
More Than ABO and Rh
When people think of blood types, they picture the familiar A, B, AB, and O labels along with “positive” or “negative” for Rh. Those two systems matter enormously, but they are just the beginning. The ABO antigens are built by enzymes that add specific sugars onto a precursor chain sitting on the red blood cell surface. A and B blood types carry an extra sugar (GalNAc or galactose, respectively) on top of the core structure found on O-type cells. The enzymes that attach those sugars are the direct products of the ABO genes, so your blood type is really a story about which sugar-adding enzymes your DNA codes for.1FEMS Microbiology Immunology. The ABO, Lewis and related blood group antigens; a review of structure and biosynthesis Early degradation experiments showed that stripping a single sugar off an antigen could expose an entirely different blood group specificity, confirming that the system is built layer by layer.2PubMed. Unravelling the biochemical basis of blood group ABO and Lewis antigenic specificity
The Rh system alone is one of the most complex and immunogenic blood group systems known. It involves two distinct proteins that carry the C, c, E, e, and D antigens, and researchers have mapped out the molecular basis of many of these variants over the past few decades.3Blood. The Rh blood group system: a review Beyond Rh, the Kell, Kidd, Duffy, Lewis, MNS, and dozens of other systems each present their own antigens and can each cause clinical trouble if a patient develops antibodies against them.
How Blood Group Antigens Connect to Infectious Disease
One of the most striking stories in immunohematology has nothing to do with transfusion. The Duffy blood group antigen doubles as a receptor for the malaria parasite Plasmodium vivax. People who lack the Duffy antigen on their red cells, a phenotype common in sub-Saharan Africa, are resistant to P. vivax invasion. The parasite simply cannot latch onto the cell.4PubMed. Duffy blood group and malaria The Duffy antigen also serves as a receptor for inflammatory signaling molecules called chemokines, and laboratory experiments showed that those chemokines could actually block the parasite’s binding protein from attaching to red cells, raising the prospect of receptor-blockade strategies for malaria therapy.5PubMed. A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor
The molecular basis of the Duffy-negative phenotype in Black individuals involves a single point mutation that silences expression on red cells. This is a textbook example of how natural selection can shape blood group frequencies. A surface molecule that happens to be a pathogen’s gateway gets switched off in populations where that pathogen is endemic, and the trait spreads because it confers a survival advantage.
Why Blood Group Diversity Persists
If lacking a blood group antigen can protect against disease, you might wonder why everyone in a given population doesn’t eventually lose it. The Rh D antigen offers a compelling case study. A large cross-sectional study found that RhD-negative individuals fared worse in measures of physical and mental health compared to people who were RhD-positive, but RhD-positive heterozygotes (carrying one copy of each allele) enjoyed better health than either homozygous group. The researchers even found preliminary evidence that RhD-positive homozygotes might suffer worse health than RhD-negative homozygotes, supporting the idea that Rh D polymorphism is maintained by heterozygote advantage, a form of balancing selection.6PubMed. The role of balancing selection in maintaining human RhD blood group polymorphism: A preregistered cross-sectional study In other words, having a mix of alleles in the population may be the evolutionary sweet spot, which helps explain why these blood group variants have stuck around for so long rather than converging on a single “best” type.
Hemolytic Transfusion Reactions
The most feared consequence of a blood group mismatch during transfusion is a hemolytic transfusion reaction, where the recipient’s immune system attacks the donated red cells. An acute reaction, typically triggered by ABO incompatibility, unfolds within minutes to hours. The recipient’s antibodies bind the foreign cells, setting off complement activation, cytokine release, and a cascade that can cause dangerously low blood pressure, disseminated intravascular coagulation (widespread abnormal clotting), kidney failure, and shock.7PubMed Central. Hemolytic Transfusion Reactions The whole process shares many features with the body’s generalized inflammatory response to severe infections or injuries.8PubMed. Pathophysiology of hemolytic transfusion reactions
Delayed hemolytic transfusion reactions are more subtle and more insidious. They typically show up days to weeks after a transfusion. The hallmark is a hemoglobin level that fails to rise as expected or drops back to pre-transfusion levels. A positive direct antiglobulin test (often called a Coombs test) and a newly identified antibody in the patient’s blood confirm the diagnosis.9PubMed. Delayed haemolytic transfusion reaction due to Kidd antibodies Complement deposits (C3d) are found on circulating red cells in these cases and can remain detectable for weeks or even months after the event.10PubMed. Delayed hemolytic transfusion reactions. Evidence for complement activation involving allogeneic and autologous red cells
The Problem With Kidd Antibodies
Among the trickiest players in transfusion medicine are antibodies directed against the Kidd blood group system. Anti-Jk antibodies are notorious for being low in strength and weak in their ability to bind, and they frequently disappear from a patient’s blood after the initial immune event. A patient who was sensitized to a Kidd antigen months or years ago may test completely clean on standard pre-transfusion screens. Then, if they receive Kidd-positive red cells, their immune system mounts a rapid recall response, and the transfused cells are destroyed aggressively through both intravascular and extravascular hemolysis.11PubMed Central. Hemolytic Transfusion Reaction due to Anti Jk Antibody, a Frequently Transient and Low‐Titer Antibody Probably Not Detected in Pretransfusion Testing; A Case Report
This vanishing-antibody behavior is a genuine safety gap. Standard blood bank protocols do everything right and still miss the antibody because it is no longer detectable at the time of testing. Kidd antibodies are a leading cause of delayed hemolytic reactions for exactly this reason. The clinical lesson is that a patient’s transfusion history matters as much as their current antibody screen, and blood banks increasingly keep lifetime antibody records so that once-identified antibodies are never forgotten, even if they can no longer be measured in the lab.
Beyond Red Cells: Reactions From Antibodies, Donor Cells, and Lung Injury
Hemolytic reactions are not the only danger in transfusion. Transfusion-related acute lung injury (TRALI) is a separate and distinct complication that involves sudden respiratory distress, typically within six hours of receiving blood products. The prevailing model describes a “two-hit” process: first, the patient has some pre-existing inflammatory condition (common in surgical or intensive-care settings), and second, donor antibodies against white blood cell antigens or biologically active lipids from stored blood products trigger a massive neutrophil response in the lungs.12PubMed. Transfusion-related acute lung injury: a review
A rarer but usually fatal complication is transfusion-associated graft-versus-host disease, in which viable donor T cells in the blood product engraft in the recipient and attack the recipient’s tissues. The recipient’s immune system fails to destroy these foreign cells, and the resulting multi-organ assault is lethal in the vast majority of cases.13PubMed. Transfusion-associated graft-versus-host disease and its prevention This complication is prevented by irradiating blood products before transfusion for at-risk patients, which disables the donor lymphocytes while leaving the red cells functional.14PubMed Central. Transfusion-Associated Graft-Versus-Host Disease in Adults
Testing That Goes Beyond Serology
Traditional blood typing relies on serology: you mix a patient’s red cells with known antibodies and watch for clumping. The direct antiglobulin test detects antibodies or complement already stuck to a patient’s red cells in the body, while the indirect antiglobulin test detects free-floating antibodies in the patient’s serum that can bind red cells in a test tube.15CMAJ. The role of the Coombs test in evaluating hemolysis in adults These tests have been workhorses of transfusion medicine for decades, and they remain central to everyday practice.
But serology has a significant blind spot when it comes to patients who receive frequent transfusions. If your blood contains a mixture of your own red cells and recently donated cells, serological typing can produce misleading results because the reagents react with the donor cells still circulating in your bloodstream. Genotyping, which reads the patient’s DNA rather than probing the surface of whatever red cells happen to be present, sidesteps this problem entirely. In one study of 79 multiply-transfused patients, discrepancies between serological phenotype and genotype-derived phenotype turned up in over 40 percent of the chronically transfused subset, and genotyping proved critical for selecting safe blood for future transfusions.16PubMed Central. Benefits of blood group genotyping in multi-transfused patients from the south of Brazil Another study of 37 patients found discrepancies in over half, with about a third of those discrepancies carrying a real risk of triggering new antibody formation.17PubMed. Blood group genotyping in multi-transfused patients
Real-time PCR platforms have made genotyping faster and more accessible. Researchers have validated these methods for multiple blood group systems, including Rh, Kidd, and Duffy, and shown that they produce reliable results even when serological methods fall short.18PubMed. Importance of extended blood group genotyping in multiply transfused patients For patients with conditions like sickle cell disease or thalassemia who may need dozens or hundreds of transfusions over a lifetime, accurate genotyping is not a luxury. It is a safety necessity.
Autoimmune Hemolytic Anemia
Sometimes the problem is not a mismatch between two people’s blood. Instead, the patient’s own immune system turns against their red cells. Autoimmune hemolytic anemia (AIHA) is classified by the type of antibody involved. Warm AIHA involves antibodies (usually IgG) that bind red cells most effectively at body temperature, while cold AIHA involves antibodies (usually IgM) that work best at lower temperatures, like those in the fingers and toes during chilly weather. The direct antiglobulin test helps distinguish the two forms: warm AIHA typically shows IgG coating the cells, while cold AIHA shows complement component C3d.19PubMed. Autoimmune hemolytic anemia: causes and consequences
Cold agglutinin disease, the most common form of cold AIHA, is driven by complement activation that leads to both intravascular hemolysis (red cells bursting inside blood vessels) and extravascular hemolysis (red cells being snagged and destroyed in the liver and spleen). About 90 percent of cold agglutinins are IgM class antibodies, and they need to reach a titer of at least 1:64 at 4°C to be clinically meaningful.20PubMed Central. Cold Agglutinin Disease Patients with cold agglutinin disease can experience flares during cold exposure, and one of the first-line recommendations is simply staying warm.
When Medications Trigger Red Cell Destruction
Certain drugs can cause immune hemolytic anemia by provoking antibodies that either need the drug present to attack red cells or that go on to attack red cells independently. Cephalosporin antibiotics, for example, are among the most commonly implicated drugs for the drug-dependent type: the antibody only reacts when the drug is part of the picture. Fludarabine, a chemotherapy agent, works differently. It disrupts the immune system in a way that causes the body to produce autoantibodies against its own red cells, and the resulting anemia looks identical to ordinary AIHA until you realize it goes into remission once the drug is stopped.21PubMed. Drug-induced immune hemolytic anemia
The mechanisms behind drug-induced hemolysis remain a subject of debate. Some drugs, like penicillin, bind tightly to proteins on the red cell surface, turning the cell into a target for drug-specific IgG antibodies. Other drugs bind more loosely and generate antibodies that can activate complement, leading to acute hemolysis inside the blood vessels and sometimes kidney failure. Fatalities are more common in this latter group.22Immunohematology. Drug-induced immune hemolytic anemia: the last 30 years of changes For clinicians, the key is recognizing that a new drug could be the culprit whenever a patient develops unexpected anemia with a positive direct antiglobulin test.
Platelet Immunology and Neonatal Thrombocytopenia
Immunohematology does not stop at red blood cells. Platelets carry their own set of antigens, including HLA Class I molecules shared with most nucleated cells. When a patient who has been exposed to foreign HLA antigens through previous transfusions or pregnancies receives platelet transfusions, their alloantibodies can destroy the donated platelets within hours, leaving the patient with dangerously low platelet counts and no benefit from the transfusion. This is called platelet transfusion refractoriness, and it creates a serious bleeding risk.23PubMed Central. Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: From mechanisms and determinants to therapeutic prospects
Platelets also carry a separate family of antigens called human platelet antigens (HPAs), and mismatches for these can cause a condition in newborns called fetal and neonatal alloimmune thrombocytopenia (FNAIT). This occurs when a pregnant person makes antibodies against a platelet antigen the fetus inherited from the other parent, most frequently HPA-1a on a protein called integrin β3.24PubMed. Fetal and neonatal alloimmune thrombocytopenia: Current pathophysiological insights and perspectives for future diagnostics and treatment These maternal antibodies cross the placenta and destroy fetal platelets, causing intracranial hemorrhage in roughly 10 to 20 percent of affected babies. Research has shown that the severity of disease depends not just on antibody levels but on structural features of the antibody itself, such as how much fucose is attached to its backbone: less fucose means stronger interaction with immune cells and worse outcomes for the fetus.25PubMed. Anti-HPA-1a fetal-neonatal alloimmune thrombocytopenia: reframing diagnostics, pathophysiology, and management
Prevention of Rh Disease in Pregnancy
One of immunohematology’s greatest success stories is the prevention of hemolytic disease of the fetus and newborn caused by Rh D incompatibility. When an RhD-negative person carries an RhD-positive fetus, fetal red cells that enter the maternal circulation can trigger anti-D antibody production. In subsequent pregnancies with RhD-positive fetuses, those antibodies cross the placenta and destroy fetal red cells, potentially causing severe anemia, heart failure, or stillbirth.
The standard prevention is an injection of anti-D immunoglobulin (commonly known as RhoGAM) during pregnancy and after delivery. The injected antibodies coat any fetal red cells that have entered the maternal bloodstream, clearing them before the mother’s immune system mounts its own antibody response. The mechanism of this suppression, called antibody-mediated immune suppression (AMIS), is still not fully understood. Animal model research has shown that IgG-mediated clearance of the foreign red cells alone is not sufficient to prevent the antibody response. The injected antibodies appear to block early B-cell activation but do not prevent T-cell responses or the formation of immunological memory.26Current Opinion in Hematology. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn: what can we learn from rodent models? In practice, this means the prevention is highly effective but not infallible, and understanding why it sometimes fails remains an active area of investigation.
Enzymatic Conversion Toward Universal Donor Blood
One of the most ambitious goals in the field is creating universal donor red blood cells by stripping the A and B sugar antigens off the cell surface, converting any blood type into the functional equivalent of type O. Because A and B types differ from O only by that single extra sugar on each red cell, the idea is straightforward in principle: find an enzyme that cleanly clips off the right sugar without damaging the cell. Researchers have identified glycosidase enzymes capable of doing this, and the concept has been validated in laboratory settings.27PubMed Central. Toward universal donor blood: Enzymatic conversion of A and B to O type
The practical challenges are considerable. The enzyme must be efficient enough to remove virtually every antigen molecule on every cell in a unit of blood; even a small residual amount of A or B antigen could trigger a reaction in a sensitized recipient. The enzyme itself must be removed or inactivated before the blood is transfused. And the converted cells need to survive normally once inside the recipient’s circulation. Progress has been encouraging but uneven. Newer enzyme candidates, particularly those sourced from gut bacteria that naturally break down the same sugar structures in the intestinal lining, show dramatically improved efficiency compared to earlier attempts. If the approach eventually reaches clinical use, it would ease chronic shortages of type O blood and simplify emergency transfusion, though it would not address the many non-ABO blood group antigens that also cause reactions.